Physician profile
Larry A Jinks
NPI 1750485306
$2,727.58
in general payments reported to CMS, 2019-2025
37 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $433 · 2021: $695 · 2022: $342 · 2023: $330 · 2024: $186 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656 · Entertainment: $15.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $656.24 |
| Entertainment | $15.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $332.45 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $327.19 | 2019-2025 | Repatha, Otezla, Evenity |
| Amarin Pharma, INC. | $308.79 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $297.47 | 2019-2023 | Breztri |
| Pfizer INC. | $161.92 | 2019-2023 | |
| Lilly USA, LLC | $141.11 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $125.59 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.16 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $92.71 | 2022 | |
| Allergan, INC. | $62.91 | 2019-2022 | |
| Abbvie INC. | $62.40 | 2021 | |
| Astellas Pharma US INC | $59.51 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $58.01 | 2019-2025 | Capvaxive, Gardasil 9 |
| E.R. Squibb & Sons, L.L.C. | $56.28 | 2019-2022 | |
| Mannkind Corporation | $46.38 | 2023 | Afrezza |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Jinks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.